Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

(2020) Hong Deng et al.   BMC Neurology

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy

(2020) Kathleen Mullin et al.   NEUROLOGY

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody

(2019) William Kielbasa et al.   CEPHALALGIA

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

(2019) Robert Croop et al.   LANCET

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

(2019) Richard B. Lipton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine

(2019) Richard B. Lipton et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ubrogepant for the Treatment of Migraine

(2019) David W. Dodick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics–small molecule drug interactions

(2017) Pankajini Mallick et al.   Expert Opinion on Drug Metabolism & Toxicology

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics interactions of monoclonal antibodies

(2016) Nicola Ferri et al.   PHARMACOLOGICAL RESEARCH

The International Classification of Headache Disorders, 3rd edition (beta version)

(2013)   CEPHALALGIA

BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

(2013) Ronald Marcus et al.   CEPHALALGIA

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1

(2012) S.D. Silberstein et al.   NEUROLOGY